Skip to main content
Top
Published in:

Open Access 01-11-2024 | Radiotherapy | Research

Quality of life in disease-free survived patients with early-stage extranodal nasal-type NK/T-cell lymphoma after definitive intensity-modulated radiotherapy: a cross-sectional study of 310 cases

Authors: Yi-Yang Li, Yi-Min Li, Shao-Qing Niu, Han-Yu Wang, Yu-Ming Ye, Yue-Tong Zhang, Ji-Jin Wang, Yu-Jing Zhang

Published in: Supportive Care in Cancer | Issue 11/2024

Login to get access

Abstract

Purpose

Radiotherapy is a critical treatment for early-stage extranodal nasal-type NK/T-cell lymphoma (ENKTL) and has yielded favorable survival outcomes. However, their postradiotherapy quality of life (QOL) has not been investigated. Here, we conducted a cross-sectional study to assess the QOL of ENKTL patients with disease-free survival after definitive radiotherapy and to identify factors associated with QOL and treatment optimization.

Methods

This cross-sectional study included 310 patients with stage I–II ENKTL of the upper aerodigestive tract (UADT) who had received simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) with a consistent design and achieved disease-free survival. The median postradiotherapy time was 47.2 months (range, 3.1–115.7). The EORTC QLQ-H&N35 questionnaire was used to assess symptom-related QOL, and nine additional items were added to incorporate nasal, optical, and aural-related symptoms. The scores indicate the severity of the symptoms.

Results

The most common postradiotherapy symptoms among patients with ENKTL were nose problems (49.7%), dry mouth (44.8%), tooth problems (41.3%), sensory problems (32.6%), and less sexuality (25.8%). Tooth problems had the highest average score of 18.6, which is still acceptable. The severity of these symptoms decreased over time and reached a plateau in the second year after radiotherapy. Multivariable regression analysis showed that whole-neck irradiation was an independent predictive factor for xerostomia (P = 0.013, OR = 1.114), while age > 60 years was a predictive factor for lower sexuality (P < 0.001, OR = 1.32).

Conclusion

The QOL of patients with early-stage ENKTL after radiotherapy was favorable, and most symptoms improved over time. Radiotherapy was correlated with specific symptoms, which may suggest a direction for further improvement in SIB-IMRT.
Appendix
Available only for authorised users
Literature
5.
8.
go back to reference Niu SQ, Li YY, Shao H, Hu J, Wang JJ, Wang HY et al (2024) Phase 2 clinical trial of simultaneous boost intensity modulated radiation therapy with 3 dose gradients in patients with stage I-II nasal type natural killer/T-cell lymphoma: long-term outcomes of survival and quality of life. Int J Radiat Oncol, Biol, Phys 118(3):770–780. https://doi.org/10.1016/j.ijrobp.2023.09.031CrossRefPubMed Niu SQ, Li YY, Shao H, Hu J, Wang JJ, Wang HY et al (2024) Phase 2 clinical trial of simultaneous boost intensity modulated radiation therapy with 3 dose gradients in patients with stage I-II nasal type natural killer/T-cell lymphoma: long-term outcomes of survival and quality of life. Int J Radiat Oncol, Biol, Phys 118(3):770–780. https://​doi.​org/​10.​1016/​j.​ijrobp.​2023.​09.​031CrossRefPubMed
15.
go back to reference Bjordal K, Ahlner-Elmqvist M, Tollesson E, Jensen AB, Razavi D, Maher EJ et al (2009) Development of a European Organization for Research and Treatment of Cancer (Eortc) questionnaire module to be used in quality of life assessments in head and neck cancer patients. Acta Oncol 33(8):879–885. https://doi.org/10.3109/02841869409098450CrossRef Bjordal K, Ahlner-Elmqvist M, Tollesson E, Jensen AB, Razavi D, Maher EJ et al (2009) Development of a European Organization for Research and Treatment of Cancer (Eortc) questionnaire module to be used in quality of life assessments in head and neck cancer patients. Acta Oncol 33(8):879–885. https://​doi.​org/​10.​3109/​0284186940909845​0CrossRef
16.
go back to reference Patterson JM, Lu L, Watson LJ, Harding S, Ness AR, Thomas S et al (2021) Associations between markers of social functioning and depression and quality of life in survivors of head and neck cancer: findings from the Head and Neck Cancer 5000 study. Psycho-Oncol 31(3):478–485. https://doi.org/10.1002/pon.5830CrossRef Patterson JM, Lu L, Watson LJ, Harding S, Ness AR, Thomas S et al (2021) Associations between markers of social functioning and depression and quality of life in survivors of head and neck cancer: findings from the Head and Neck Cancer 5000 study. Psycho-Oncol 31(3):478–485. https://​doi.​org/​10.​1002/​pon.​5830CrossRef
17.
go back to reference Hoffmann C, Rating P, Bechrakis N, Eckstein A, Sokolenko E, Jabbarli L et al (2022) Long-term follow-up and health-related quality of life among cancer survivors with stage IEA orbital-type lymphoma after external photon-beam radiotherapy: results from a longitudinal study. Hematol Oncol 40(5):922–929. https://doi.org/10.1002/hon.3053CrossRefPubMed Hoffmann C, Rating P, Bechrakis N, Eckstein A, Sokolenko E, Jabbarli L et al (2022) Long-term follow-up and health-related quality of life among cancer survivors with stage IEA orbital-type lymphoma after external photon-beam radiotherapy: results from a longitudinal study. Hematol Oncol 40(5):922–929. https://​doi.​org/​10.​1002/​hon.​3053CrossRefPubMed
21.
go back to reference Zheng L, Tong L, Du F, Ren H, Xiao L (2021) Effect of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy on parotid gland function and quality of life in patients with nasopharyngeal carcinoma. Am J Transl Res 13(5):5272–5279PubMedPubMedCentral Zheng L, Tong L, Du F, Ren H, Xiao L (2021) Effect of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy on parotid gland function and quality of life in patients with nasopharyngeal carcinoma. Am J Transl Res 13(5):5272–5279PubMedPubMedCentral
Metadata
Title
Quality of life in disease-free survived patients with early-stage extranodal nasal-type NK/T-cell lymphoma after definitive intensity-modulated radiotherapy: a cross-sectional study of 310 cases
Authors
Yi-Yang Li
Yi-Min Li
Shao-Qing Niu
Han-Yu Wang
Yu-Ming Ye
Yue-Tong Zhang
Ji-Jin Wang
Yu-Jing Zhang
Publication date
01-11-2024
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2024
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-024-08932-2

Other articles of this Issue 11/2024

Supportive Care in Cancer 11/2024 Go to the issue
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

  • Webinar | 01-10-2024 | 12:30 (CEST)

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Get a reminder for the on-demand version